Wells Fargo & Company Sage Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
2 transactions
Others Institutions Holding SAGE
# of Institutions
218Shares Held
47.9MCall Options Held
854KPut Options Held
195K-
Vanguard Group Inc Valley Forge, PA6.42MShares$37.3 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$31.8 Million0.99% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$30.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$25.9 Million0.81% of portfolio
-
State Street Corp Boston, MA2.47MShares$14.4 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $345M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...